Pharma's Almanac TV
PA TV
Your Name
Your Email
Manage Account
Sign Out
Sign In
Register
Follow the Journey
Companies On The Road
Arcadis DPS Group
C2 Pharma
CAI
EcoLab
Environmental Systems Corporation
Federal Equipment Company
Globyz Biopharma Services
Grifols
Integrity
Nu-Tek BioSciences
PHARMALEX
Waters Corporation
Follow the Journey
Companies On The Road
ABS
aCGT Vector
Alconox Inc.
Andelyn Biosciences
Arranta Bio
Avid Bioservices
BDD
BIOVECTRA
DPS Group
Dynamk Capital
Environmental Systems Corporation
Federal Equipment Company
Genesis AEC
Globyz Biopharma Services
Grifols Partnership
IDT Biologika
Inceptor Bio
IPS-Integrated Project Services
Kineticos Life Sciences
MilliporeSigma
Montana BioScience Alliance
Olon
Rentschler Biopharma
SanaClis
Scorpion Biological Services
Secant Group
Tapemark
VITRONIC
Follow the Journey
Companies On The Road
AES Clean Technology
Altis Biosystems
Arranta Bio
Avara Pharmaceutical Services
Avid Bioservices
BioVectra
Centaur BPS
Dynamk Capital
ECRI
Evolve Biologics
Federal Equipment Company
Globyz
Inceptor Bio
IPS-Integrated Project Services
Olon
Pii
Polpharma Biologics
PPD
RoosterBio
SanaClis
Sanofi AIS
SGD Pharma
SPI Pharma
TriRx Pharmaceutical Services
Yourway
Dashboard
Topics
Products
ADC
API - Small Molecule
Biologics
Biopharmaceuticals
Biosimilars
Cell and Gene Therapy
DNA
Drug Product
Drug Substance
Equipment
Generics
Immunotherapy
Injectables
Monoclonal Antibody
Novel Therapeutics
Oral Solid Dosage
Orphan Drugs
Parenterals
Stem Cells
Vaccine
Services
Big Data
Bioprocessing
Clinical Trials
Continuous Manufacturing
Diagnostics
Drug Delivery
Drug Development
Drug Discovery
Facility
Formulation
Innovation
Oncology
Patient Adherence
Patient Centric
Preclinical
Process Development
Quality
Regulatory
Research
Serialization
Segment
Biomanufacturing
Biotechnology
CDMO
Consulting
CRO
Engineering
Equipment
Excipients
Healthcare
Intermediates
Logistics
Manufacturing
Packaging
Supply Chain
Business
Agreement
Appointment
Business
Capacity Expansion
Collaboration
Growth
Investment
Licensing
M&A
Market Expansion
Market Intelligence
Market Prediction
New Facility
Strategic Partnership
Magazine
Archive
Reports
Nice Insight Reports
2022 Sterile
2023 Cell & Gene Therapy
2023 mAb and Recombinant Protein
2024 API
2024 OSD
2024 ADC
2024 mRNA
2024 Mammalian Cell Culture
2024 Microbial Cell Culture
2024 Plasmids
2024 Gene Therapy
2024 Cell Therapy
2024 Sterile
Community
Company A to Z
Follow the Journey
Companies On The Road
Follow The Artist
Follow the Journey
Companies On The Road
More+
Staffing
Media Kit
Gilead Sciences, Inc.
38 Articles Available
0
2
Can't find what you're looking for? Try our
advanced search
.
FDA Approval
FDA Approves Trodelvy®, the First Treatment for Metastatic Triple-Negative Breast Cancer Shown to Improve Progression-Free Survival and Overall Survival
PR-M04-21-007
Licensing
ProteoNic Announces Licensing of its 2G UNic™ Technology Platform for Production of Biologics to Gilead Sciences
PR-M11-20-004
M&A
Gilead Sciences to Acquire Immunomedics
PR-M09-20-NI-18
COVID-19
Gilead’s Remdesivir Receives FDA Emergency Use Authorization for the Treatment of Patients With Moderate COVID-19
PR-M08-20-NI-48
Strategic Partnership
Gilead Sciences and Arcus Biosciences Complete Closing of Their 10-Year Partnership to Co-Develop and Co-Commercialize Next-Generation Cancer Immunotherapies
PR-M07-20-NI-021
COVID-19 Trial Data
Gilead Presents Additional Data on Investigational Antiviral Remdesivir for the Treatment of COVID-19
PR-M07-20-NI-015
M&A
Gilead Sciences Secures Exclusive Option to Acquire Pionyr Immunotherapeutics
PR-M06-20-NI-028
Partnership
Gilead Sciences and Arcus Biosciences Establish 10-year Partnership to Co-develop and Co-commercialize Next-generation Cancer Immunotherapies
PR-M05-20-NI-041
COVID-19 Treatment
Mylan to Supply Investigational Antiviral Remdesivir for the Potential Treatment of COVID-19
PR-M05-20-NI-018
Gilead Sciences Statement on Access to Remdesivir Outside of Clinical Trials
PR-M04-20-NI-003
M&A
Gilead to Acquire Forty Seven for $4.9 Billion
PR-M03-20-NI-003
Coronavirus
Gilead Sciences Initiates Two Phase 3 Studies of Investigational Antiviral Remdesivir for the Treatment of COVID-19
PR-M02-20-NI-037
Coronavirus
Gilead Sciences Begins Trial on Treatment for Coronavirus (2019-nCoV)
PR-M02-20-NI-003
Licensing
Gilead Licenses Antiviral Candidates from Novartis
PAO-M08-19-NI-019
Collaboration
Gilead and Galapagos Enter Into Transformative Research and Development Collaboration
PR-M07-19-NI-046
Capacity Expansion
Kite Announces Plans to Bolster Industry-Leading Cell Therapy Manufacturing Capabilities With New Viral Vector Facility
PR-M07-19-NI-043
Announcement
AbCellera Announces Therapeutic Antibody Discovery Collaboration with Gilead in Infectious Disease
PR-M06-19-NI-017
Appointment
Gilead Sciences Appoints Johanna Mercier as Chief Commercial Officer
PR-M05-19-NI-081
HIV
Gilead Sciences to Provide Free Truvada for PrEP® to Support U.S. Initiative to End the HIV Epidemic
PR-M05-19-NI-038
Leadership
Changes Coming to Gilead Under New Top Exec
PAO-M05-19-NI-016
Financial Results
Gilead Sciences Announces First Quarter 2019 Financial Results
PR-M05-19-NI-018
Milestone Payment
Agenus Milestone Triggers $7.5M Payment from Gilead
PR-M03-19-NI-047
Immuno-oncology
Gilead Invests in Immuno-oncology
PAO-M01-19-NI-001
Appointment
Roche Exec Moves to Gilead
PAO-M12-18-NI-010
«
0
2
»
.svg)